Cytochrome P450 1B1 (CYP1B1) converts xenobiotics to carcinogens and how lifestyle choices may interact with CYP1B1 polymorphisms and affect prostate cancer risk was assessed. Blood genomic DNA from a Caucasian population was analysed at polymorphic sites of the 5 0 untranslated region of CYP1B1 using TaqMan genotyping assays. Overall, drinker status and minor alleles at rs2551188, rs2567206
identifying risks in the carcinogenesis process is an important step towards its prevention.
Lifestyle factors such as tobacco smoking and alcohol consumption are established risks for various types of cancers. 3, 4 Worldwide, tobacco smoking accounts for roughly 21% of cancer deaths with 29% in high-income countries. 3 In the USA in the year 2010, the estimated death rate of all cancers due to cigarette smoking was roughly 38% with about 112 000 deaths among men aged 35 years or older and does not include additional deaths from environmental tobacco smoke or usage of cigars, pipes or smokeless tobacco. 5 In prostate, a meta-analysis of 4 million cohort participants showed that current cigarette smoking was correlated with increased risk of cancer death (relative risk [RR]; 1.24, 95% confidence interval [CI];
1.18-1.31) with cigarettes smoked per day having a dose-response association with cancer mortality. 6 Also, compared with non-smokers, former smokers (hazard ratio [HR]; 1.63, 95% CI; 1.30-2.04, P < .001) and current smokers (HR; 1.80, 95% CI 1.45-2.24, P < .001) had a higher risk of prostate cancer biochemical recurrence. 7 Alcohol consumption accounts for about 5% of all cancer deaths worldwide and a large proportion of cancers in Europe and America. 3 In the USA, 92% of respondents 18 years and older claimed life-time alcohol usage 8 and up to 3.7% of cancer deaths were linked to drinking in the USA. 9 In a meta-analyses study, Bagnardi et al 4 find alcohol drinking to be associated with various cancers and this effect is strongest among heavy drinkers. The effect of alcohol drinking appears to be dose-dependent as light to moderate drinking resulted in a lower risk, whereas heavy drinking caused an increased risk of certain cancers. 10 As for prostate, a dose-response was also observed for cancer risk among current drinkers (P trend < .01).
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Tobacco smoking and alcohol thus play a causative role in the carcinogenesis process, and a major enzyme that affects this process is cytochrome P450 (CYP) 1B1. CYP1B1 is a member of the CYP superfamily involved in phase I metabolism of many xenobiotics. 12, 13 CYP1B1 can metabolically convert tobacco smoke pro-carcinogens such as polycyclic aromatic hydrocarbons to reactive or carcinogenic intermediates 13, 14 and result in DNA adduct formation. 14, 15 In prostate, mRNA transcripts including CYP1B1 were observed along with DNA adducts after incubating with 2-amino-1-methyl-6-phenylimiazo [4,5-b] pyridine (PhIP), 2-amino-3-methylimidazo [4,5- 
f]quinoline (IQ) and benzo[a]pyrene (B[a]P).
14 Also in primary mammary epithelial cells, B[a]P caused DNA adducts to form as well as CYP1B1
induction. 15 Alternatively, PAHs or smoking can enhance levels of CYP1B1 expression. 13, 16 As CYP1B1 is expressed in human prostate, 17 gene up-regulation and activation of pro-carcinogens may thus be influential in the prostatic carcinogenesis process.
The main form of alcohol in alcoholic beverages is ethanol, which may pose a risk even at moderate drinking amounts. 18 Levels of ethanol in blood were shown to dramatically rise above 15 mmol/L within 30 minutes after drinking whisky (0.72 g/kg ethanol) and gradually decreased over a 6 hour period. 19 Although the tumorigenicity of ethanol itself may be dependent on experimental conditions, its direct metabolic product acetaldehyde has been shown to be carcinogenic in animals. 20 Indeed, CYP1B1 was shown to metabolize ethanol into significant amounts of acetaldehyde 21 and studies in rats show inhalation and oral administration of acetaldehyde to be carcinogenic in animals. 22, 23 
| Cell culture
Caucasian prostate cancer PC3 and DU145 cell lines were obtained from American Type Cell Collection (ATCC, Manassas, VA, USA).
Cells were cultured in RPMI1640 medium supplemented with 10%
foetal bovine serum in a humidified atmosphere containing 5% CO2.
These cell lines were authenticated by DNA short-tandem repeat analysis by ATCC, and experiments with cell lines were performed within 6 months of their revival.
| Immunohistochemical analysis
Immunostaining of CYP1B1 was performed on specimens of BPH. for a dominant pattern was observed to be a significant risk for prostate cancer. The adjusted OR for C/T+T/T compared with major genotype C/C was 1.38 with a 95% CI of 1.04 to 1.83 for rs2567206 and at rs10175368, G/A+A/A compared with major G/G had an adjusted OR of 1.52 with 95% CI of 1.14 to 2.02. Likewise, the minor allele T and A were also observed to be significantly increased in PC at rs2567206 (P = .008) and rs10175368 (P = .001),
| Statistical analyses
respectively. Additionally, minor allele A at rs2551188 proved to be a risk for cancer (P = .043). No differences were found between patients with prostate cancer and control at other polymorphic sites.
| Linkage disequilibrium of CYP1B1 polymorphisms
Linkage between the polymorphic sites of CYP1B1 was calculated and 
| Haplotype frequencies of CYP1B1 polymorphic sites
Haplotype frequencies of rs2551188-rs2567206-rs2567207-rs1017
5368 and rs163090-rs162330-rs162331 in patients with prostate cancer were calculated and results are shown in Table 4 . The major haplotype was G-C-T-G for rs2551188-rs2567206-rs2567207-rs10175368, which was expressed in 70.7% of healthy individuals overall. Interestingly, G-C-T-G represents major allele at the respective rs sites and was significantly reduced in prostate cancer when compared to other haplotypes combined (P = .028). For rs163090-rs162330-rs162331, 2 haplotypes were similarly expressed and predominant, being T-T-G (47.7%) and A-G-A (46.6%) in overall controls. These haplotypes involving rs163090, rs162330 and rs162331, however, did not show any significant differences between cases and controls.
| CYP1B1 polymorphisms within clinical stage of prostate cancer patients
Prostate cancer samples were classified in terms of clinical stage.
There were 82 samples of unknown status. No statistical differences were observed when classified in terms of stage ≤2 (N = 253) vs ≥3
(N = 65) for all CYP1B1 polymorphic sites (data not shown).
| Influence of lifestyle factors on risks of CYP1B1 polymorphisms for prostate cancer
As lifestyle factors can affect risks of prostate cancer, interaction between choices and CYP1B1 polymorphisms were determined. Alcohol drinker status and its interaction with CYP1B1 polymorphisms and cancer risks are shown in Table 6 . In non-drinkers, none of the polymorphic sites were associated for prostate cancer with the exception for a trend for rs10175368 allele (P = .051). In contrast among drinkers, significant associations for cancer was observed for both genotypic and allelic frequencies at rs2567206 (P = .026 and P = .044, respectively) and rs10175368 (P = .012 and P = .016, respectively). At rs2567206, adjusted OR (95% CI) com- Interaction between lifestyle choices and CYP1B1 haplotypes was also determined. The effect of smoker and drinker status on prostate cancer risks for haplotype frequencies of rs2551188-rs2567206-rs2567207-rs10175368 and rs163090-rs162330-rs162331 is shown in Table 4 . Interestingly compared to healthy controls, major G-C-T-G of rs2551188-rs2567206-rs2567207-rs10175368 was significantly lower in cancer among smokers (P = .036) with a tendency for drinkers (P = .066), whereas no associations were observed in non-smokers and non-drinkers. Lifestyle factors did not influence the risks for any of the rs163090-rs162330-rs162331 haplotypes.
| CYP1B1 polymorphisms and protein expression among BPH specimens
As genotypes and haplotypes were observed to be a risk for prostate cancer, expression level of CYP1B1 protein was evaluated for all sites. Immunohistochemistry was performed on 83 BPH specimens and scored. Interestingly compared to major genotype, variants at rs2551188 (P = .015), rs2567206 (P =.016) and rs10175368 (P = .047) were determined to have increased CYP1B1 levels (Figure 1A) . Other polymorphic sites, however, showed no correlations with CYP1B1 expression (data not shown).
| CYP1B1 polymorphisms and promoter activity
To assess functional properties, all polymorphic sites were evaluated for promoter activity by site-directed mutagenesis followed by luciferase activity. Although minor alleles of rs2551188 and rs2567206 had no effect, rs10175368. A significantly up-regulated CYP1B1 promoter activity compared to major allele G in both PC3 and DU145 cells (P < .001, Figure 1B ). Other polymorphisms did not affect promoter activity (data not shown).
| Nuclear extract binding of polymorphic site
Promoter activity was enhanced due to polymorphism, and thus, the binding capability of nuclear extracts to polymorphic sites was analysed. Nuclear extract was observed to weakly bind to rs10175368 G allele motif but interestingly, a 2.1-fold larger amount of protein bound to the minor A allele form (P = .045, Figure 1C ). Binding of nuclear extracts to motifs of rs2551188 and rs2567206 was not observed (data not shown). 11 and one of the main carcinogenic factors is acetaldehyde, which is derived from ethanol through cellular enzymes and CYP1B1 has been shown capable of this con-
T A B L E 4 Influence of lifestyle choices on frequencies of major haplotypes of rs2551188-rs2567206-rs2567207-rs1017536 (G-C-T-G) and rs163090-rs162330-rs162331 (A-G-A and T-T-G) of
version. 21 Studies demonstrate acetaldehyde to affect cellular properties such as DNA synthesis and repair, 24 cause DNA mutations and adducts 24, 25 and undergo further metabolism to form reactive radicals that can bind DNA. 26 For smokers, although only a near trend was observed as a risk for prostate cancer in this study (P = .109), meta-analysis shows a significant correlation for current smoking. 6 A possible reason for the meagre significance may be due to the lack of information regarding the amount of smoking per T A B L E 5 Distribution of CYP1B1 polymorphisms (dominant pattern and allele) in healthy controls and prostate cancer patients among non-smokers (A) and current or former smokers (B) individual and perhaps a breakdown by pack-years may show a significant risk among heavy smokers, as a dose-response effect of smoking was observed for prostate cancer mortality. 6 Tobacco smoke contains numerous compounds that can promote cancer and agents such as polycyclic aromatic hydrocarbons (PAH) have been shown to enhance cancer of the lung, bladder, and head and neck. 12 Interestingly in prostate cancer tissue, Caucasian ever smokers had significantly higher PAH-DNA adducts compared to non-smokers. 32 When evaluating polymorphic sites of CYP1B1, the minor allele at rs2551188, rs2567206 and rs10175368 were an overall risk for prostate cancer. Interestingly when separated by lifestyle choices, none of these were associated with cancer among non-smokers and non-drinkers with the exception for a trend for rs10175368 allele among non-drinkers. These results for men who do not smoke and drink alcohol are comparable to a study performed on Hispanic and non-Hispanic Caucasians as no association for prostate cancer was observed for rs2551188 and rs2567206 by Beuten et al, 31 although breakdown by lifestyle choices was not provided. On the contrary, smoking and alcohol drinking resulted in the minor alleles and genotypes at rs2567206 and rs10175368 to be a risk for cancer. Lifestyle Polymorphisms of rs2551188, rs2567206 and rs10175368 are thus determined to be a risk for prostate cancer and the mechanism by which they may play a role is not known. These sites are located in the promoter or 5 0 UTR which are of importance as variants in this region may lead to increased gene expression 29 and, consequently, increased enzyme or CYP1B1 levels. In concordance, results of this study demonstrate polymorphisms at these 3 sites to be associated with increased CYP1B1 protein levels as was observed in human prostatic specimens. On the contrary, only the rs10175368 minor allele showed increased luciferase activity and mobility shift demonstrated strong binding towards this variant. As these sites are linked, it may thus be through the minor allele of rs10175368 that expression levels of CYP1B1 are increased. This co-dependence with rs10175368 may be pertinent for rs2567206 as cancer risk for these sites was modified by smoker and alcohol drinker status. This is corroborated in smokers as Rotunno et al 34 observed rs10175368 to have increased mRNA expression among current smokers (P = .004) but not for never and former smokers. Thus, these lifestyle factors appear to interact at the genetic level to possibly increase CYP1B1 levels with rs10175368 playing a major role. Further experimentation is necessary to determine the identity of the factor that can bind to the rs10175368 minor allele in prostate cancer cells.
SNP ID Genotype
On the other hand, risk of the rs2551188 A allele was not 
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